(Total Views: 564)
Posted On: 12/23/2022 8:01:22 AM
Post# of 148899
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) "CytoDyn" or the "Company", a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.
Webcast Access Information
Date: Thursday, December 29, 2022
Time: 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time
Access: https://event.choruscall.com/mediaframe/webca...d=i2RX9JZG
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until January 29, 2023.
https://www.cytodyn.com/newsroom/press-releas...ormance-of
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) "CytoDyn" or the "Company", a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.
Webcast Access Information
Date: Thursday, December 29, 2022
Time: 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time
Access: https://event.choruscall.com/mediaframe/webca...d=i2RX9JZG
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until January 29, 2023.
https://www.cytodyn.com/newsroom/press-releas...ormance-of
(2)
(0)
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼
